Overview

Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

Status:
Withdrawn
Trial end date:
2014-08-01
Target enrollment:
0
Participant gender:
All
Summary
This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Anidulafungin
Echinocandins
Voriconazole
Criteria
Inclusion Criteria:

- Diagnosis of proven, probable, or possible invasive aspergillosis.

- Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion Criteria:

- Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.

- Chronic invasive aspergillosis.

- Receipt of antifungal treatment for more than 96 hours.

- Severe liver dysfunction.